Q1 Earnings Forecast for FHTX Issued By B. Riley

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Analysts at B. Riley issued their Q1 2025 earnings estimates for Foghorn Therapeutics in a research note issued to investors on Thursday, March 13th. B. Riley analyst K. Patel expects that the company will earn ($0.34) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($1.34) EPS.

FHTX has been the topic of a number of other reports. Jefferies Financial Group dropped their price target on shares of Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $13.17.

Foghorn Therapeutics Stock Down 3.5 %

Shares of Foghorn Therapeutics stock opened at $4.44 on Monday. Foghorn Therapeutics has a 52-week low of $3.86 and a 52-week high of $10.25. The company’s 50-day simple moving average is $4.68 and its 200-day simple moving average is $6.54. The firm has a market cap of $246.92 million, a price-to-earnings ratio of -2.31 and a beta of 3.13.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its earnings results on Thursday, March 6th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.13. The business had revenue of $2.86 million during the quarter, compared to analysts’ expectations of $8.56 million.

Institutional Trading of Foghorn Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Zacks Investment Management purchased a new stake in shares of Foghorn Therapeutics in the third quarter valued at about $96,000. Lazard Asset Management LLC purchased a new position in Foghorn Therapeutics during the fourth quarter worth approximately $49,000. Cubist Systematic Strategies LLC purchased a new position in Foghorn Therapeutics during the fourth quarter worth approximately $51,000. XTX Topco Ltd purchased a new position in Foghorn Therapeutics during the third quarter worth approximately $101,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Foghorn Therapeutics in the fourth quarter worth $56,000. Hedge funds and other institutional investors own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.